Souhaitez-vous accéder aux communiqués récents ?

COPENHAGEN, Denmark, April 14, 2026 (GLOBE NEWSWIRE) -- Arla Foods Ingredients has developed high-protein, nutrient-dense application concepts for users of GLP-1 anti-obesity medications, which it...

San Francisco, CA, April 08, 2026 (GLOBE NEWSWIRE) -- FormBlends, a health technology platform focused on GLP-1 weight loss results and weight management provider directory listings, today announced...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that eligible Weight Watchers...

Micron Biomedical makes the Most Innovative Companies List in recognition of clinical, financial and other progress toward needle-free vaccines and drugs.

This industry-first financial innovation bypasses PBM spread pricing, ensures ERISA compliance, gives employers total control over the Budget, Behavior, an

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral...

GLP Diet is a personalized weight loss app supporting GLP-1 meds with tailored meals, workouts, trackers, and expert guidance for fast and lasting results.

Omada Health announces GLP-1 Flex Care, giving employers a new, flexible path to support obesity care

Omada Health Reports Fourth Quarter and Full-Year 2025 Results

MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.